An interventional study of EHRA-PATHS software tool in Atrial Fibrillation, sponsored by University Medical Center Groningen. Completed at 1 site in Netherlands. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Diagnostic
In elderly atrial fibrillation (AF) patients, AF is usually a manifestation of risk factors and comorbidities not only limited to cardiovascular diseases. Especially in elderly often more than two comorbidities are present. The presence of comorbidities also affects outcomes in AF patients. Current healthcare systems are single-disease focused, which increases the risk of underdiagnosing, replicating diagnostic tests and adverse drug-drug interactions, placing a high burden on healthcare costs. Healthcare systems and hospitals are in need of new care pathways to address the complexity of multimorbid AF patients and to reduce costs. The EHRA-PATHS consortium set out to address this need for change in management for multimorbid, elderly AF patients in Europe through the development of new care pathways. The aim of this study is to evaluate the current management of risk factors and comorbidities, and subsequently implement the newly developed care pathways and evaluate if these pathways lead to better management of risk factors and comorbidities in multimorbid, elderly AF patients, compared to current standard care.
3,872 studies on the registry are indexed under Atrial Fibrillation; 926 are open to participants now.
This study's enrollment of 703 is above the median of 144 across 2,381 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →University Medical Center Groningen is the lead sponsor of 610 studies on the registry; 174 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The health care provider will use the EHRA-PATHS' newly developed care pathways to assess whether there is an indication for presence of risk factors and comorbidities. If this is the case, the care pathways will show possible next steps for confirming the presence of these risk factors and comorbidities. If confirmed, treatment according to the current guidelines should be initiated. Since this leads to an individualized management plan, procedures can differ between patients and will also depend on local processes.
Device: EHRA-PATHS software tool
The health care provider follows current clinical practice with regards to history taking, physical examination etc.
Newly developed care pathways integrated into a care-management software tool
Identification and management of risk factors and comorbidities
The number of risk factors and comorbidities that are identified and for which treatment is initiated during base mapping and at the end of the randomized controlled trial.
Time frame: 6 months
AF symptom burden
Measured with the Atrial Fibrillation Severity Scale (AFSS) questionnaire
Time frame: 6 months
Quality of life (QoL)
Measured with the EuroQol five-dimensional five-level (EQ-5D-5L) questionnaire
Time frame: 6 months
Referrals to other disciplines
The referrals to other disciplines will consist of the number of referrals and the percentage of patients referred.
Time frame: 6 months
Patient and health care provider satisfaction
Measured with a patient and health care provider (HCP) satisfaction questionnaire
Time frame: 6 months
Healthcare resource use/costs
Measured with the iMedical Consumption Questionnaire (iMCQ)
Time frame: 6 months
HRQoL/utility
Measured with the EQ-5D-5L questionnaire (iMCQ)
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen